Drug Updates highlights information about new and revised products available in Canada that are coming to e-CPS.
It includes new molecular entities, new products or products with major changes (new indications, new
dosage forms, new formulations and reinstated products). New product information can also be found under
What's New on the Home tab.
|
Brand Name
|
Generic Name
|
Manufacturer
|
Classification
|
New Information
|
Date Entered
|
|
ACET
|
acetaminophen
|
PendoPharm
|
Analgesic - Antipyretic
|
New product
|
09/01/2010
|
|
Bi-PegLyte
|
bisacodyl/electrolytes/PEG 3350
|
PendoPharm
|
Gastrointestinal lavage
|
New product
|
09/01/2010
|
|
Cimzia
|
certolizumab pegol
|
UCB
|
Biological response modifier
|
New safety information: in the warnings and precautions, and adverse reactions sections
|
09/01/2010
|
|
Exelon
|
rivastigmine hydrogen tartrate
|
Novartis Pharmaceuticals
|
Cholinesterase inhibitor
|
New safety information: in the adverse reactions section
|
09/01/2010
|
|
Exelon Patch 5, Exelon Patch 10
|
rivastigmine
|
Novartis Pharmaceuticals
|
Cholinesterase inhibitor
|
New safety information: in the adverse reactions section
|
09/01/2010
|
|
Famvir
|
famciclovir
|
Novartis Pharmaceuticals
|
Antiviral agent
|
New safety information: in the adverse reactions section
|
09/01/2010
|
|
Fosamax
|
alendronate sodium
|
Merck Frosst
|
Bone metabolism regulator
|
New safety information: in the adverse reactions section
|
09/01/2010
|
|
Fosavance
|
alendronate sodium/cholecalciferol
|
Merck Frosst
|
Bone metabolism regulator and vitamin D
|
New safety information: in the adverse reactions section
|
09/01/2010
|
|
Gardasil
|
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
|
Merck Frosst
|
Active immunizing agent
|
New indication: for boys and men 9 through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11
|
09/01/2010
|
|
Habitrol
|
nicotine transdermal system
|
Novartis Consumer Health
|
Smoking cessation aid
|
Product reinstated
|
09/01/2010
|
|
Invega Sustenna
|
paliperidone palmitate
|
Janssen-Ortho
|
Antipsychotic agent
|
New product: extended-release injectable suspension
|
09/01/2010
|
|
Methotrexate Injection USP
|
methotrexate sodium
|
Hospira
|
Antimetabolite - Antirheumatic agent
|
New full monograph, previously availability only
|
09/01/2010
|
|
Methotrexate Tablets USP
|
methotrexate sodium
|
Hospira
|
Antimetabolite - Antirheumatic agent
|
New full monograph, previously availability only
|
09/01/2010
|
|
Precedex
|
dexmedetomidine HCl
|
Hospira
|
Alpha2-adrenergic agonist
|
New molecular entity
|
09/01/2010
|
|
Rapamune
|
sirolimus
|
Wyeth Canada
|
Immunosuppressive agent
|
New safety information: in the adverse reactions section
|
09/01/2010
|
|
Alimta
|
pemetrexed disodium
|
Lilly
|
Antineoplastic
|
New indication: maintenance treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer, in good performance status patients without disease progression immediately following four cycles of first-line platinum doublet chemotherapy, excluding pemetrexed
|
08/15/2010
|
|
Alimta
|
pemetrexed disodium
|
Lilly
|
Antineoplastic
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Aredia
|
pamidronate disodium
|
Novartis Pharmaceuticals
|
Bone metabolism regulator
|
New safety information: in the warnings and precautions, and adverse reactions sections
|
08/15/2010
|
|
Casodex
|
bicalutamide
|
AstraZeneca
|
Nonsteroidal antiandrogen
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Cialis
|
tadalafil
|
Lilly
|
cGMP-specific phosphodiesterase type 5 inhibitor
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Clolar
|
clofarabine
|
Genzyme
|
Antineoplastic agent
|
New molecular entity
|
08/15/2010
|
|
Effexor XR
|
venlafaxine HCl
|
Wyeth Canada
|
Antidepressant - Anxiolytic
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Humatrope
|
somatropin
|
Lilly
|
Growth stimulant
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
08/15/2010
|
|
Invanz
|
ertapenem sodium
|
Merck Frosst
|
Antibiotic
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Paxil
|
paroxetine HCl
|
GlaxoSmithKline
|
Antidepressant - Antiobsessional - Antipanic - Anxiolytic - Social phobia (social anxiety disorder) - Post-traumatic stress disorder
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Paxil CR
|
paroxetine HCl
|
GlaxoSmithKline
|
Selective serotonin reuptake inhibitor
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Pepto-Bismol with InstaCool
|
bismuth subsalicylate
|
Procter & Gamble
|
Diarrhea relief - Heartburn relief - Indigestion relief - Nausea Relief - Upset stomach relief
|
New product
|
08/15/2010
|
|
Rifadin
|
rifampin
|
sanofi-aventis
|
Antibiotic
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Sandoz Atorvastatin
|
atorvastatin calcium
|
Sandoz
|
Lipid metabolism regulator
|
New product
|
08/15/2010
|
|
Sandoz Azithromycin Powder for Oral Suspension
|
azithromycin monohydrate
|
Sandoz
|
Antibioitic
|
New product
|
08/15/2010
|
|
Sandoz Fentanyl Patch
|
fentanyl
|
Sandoz
|
Opioid analgesic
|
New product
|
08/15/2010
|
|
Sandoz Naratriptan
|
naratriptan HCl
|
Sandoz
|
5-HT1 receptor agonist - Migraine therapy
|
New product
|
08/15/2010
|
|
Sandoz Olanzapine ODT
|
olanzapine
|
Sandoz
|
Antipsychotic
|
New product
|
08/15/2010
|
|
Silkis
|
calcitriol
|
Galderma
|
Topical non steroidal antipsoriatic agent
|
New product
|
08/15/2010
|
|
Stelara
|
ustekinumab
|
Janssen-Ortho
|
Biological response modifier
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Volibris
|
ambrisentan
|
GlaxoSmithKline
|
Endothelin receptor antagonist
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Xatral
|
alfuzosin HCl
|
sanofi-aventis
|
Adjunctive therapy in acute urinary retention (AUR) - Symptomatic treatment of benign prostatic hyperplasia (BPH)
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Zoladex
|
goserelin acetate
|
AstraZeneca
|
Luteinizing hormone-releasing hormone (LHRH) analog
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Zoladex LA
|
goserelin acetate
|
AstraZeneca
|
Luteinizing hormone-releasing hormone (LHRH) analog
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Dexilant
|
dexlansoprazole
|
Takeda
|
Proton pump inhibitor
|
New molecular entity
|
08/15/2010
|
|
Menveo
|
meningococcal (groups A, C, Y and w-135) oligosaccharide corynebacterium diphteriae CRM197 conjugate vaccine
|
Novartis
|
Active immunizing agent
|
New product
|
08/15/2010
|
|
Gadovist
|
gadobutrol
|
Bayer
|
Contrast enhancement agent for magnetic resonance imaging (MRI)
|
New indication: expansion of the conditions for use to pediatrics aged 2-17 years of age
|
08/15/2010
|
|
Humatrope
|
somatropin
|
Lilly
|
Growth stimulant
|
New indication: for the treatment of growth failure in children born small for gestational age (birth weight and/or length below - 2 SD) and who fail to achieve catch-up growth by 2 to 4 years or later
|
08/15/2010
|
|
PMS-Risedronate
|
risedronate sodium hemi-pentahydrate
|
Pharmascience
|
Bone metabolism regulator
|
New product
|
08/15/2010
|
|
ratio-Risedronate
|
risedronate sodium hemi-pentahydrate
|
ratiopharm
|
Bone metabolism regulator
|
New product
|
08/15/2010
|
|
Rituxan
|
rituximab
|
Roche
|
Antineoplastic
|
Addition to the Rheumatoid Arthritis (RA) indication: Rituxan in combination with Methotrexate has been shown to reduce the rate of progression of joint damage as measured by x-ray
|
08/15/2010
|
|
Tasigna (issued under NOC/C policy)
|
nilotinib hydrochloride monohydrate
|
Novartis Pharmaceuticals
|
Protein-tyrosine kinase inhibitor
|
New indication: For the treatment of chronic phase Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including Imatinib
|
08/15/2010
|
|
Agrylin
|
anagrelide HCl
|
Shire
|
Platelet-reducing agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Arava
|
leflunomide
|
sanofi-aventis
|
Antirheumatic - Immunomodulator agent
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Canesoral
|
fluconazole
|
Bayer Consumer Care
|
Antifungal agent
|
New product and schedule change: 150 mg single tablet now available without a prescription
|
08/15/2010
|
|
Canesoral Combi-Pak
|
clotrimazole/fluconazole
|
Bayer Consumer Care
|
Antifungal agents
|
New product and schedule change: 150 mg single tablet now available without a prescription
|
08/15/2010
|
|
Clavulin
|
amoxicillin/clavulanic acid
|
GlaxoSmithKline
|
Antibiotic - β-lactamase inhibitor
|
New safety information: in the warnings and precautions section
|
08/15/2010
|
|
Lantus
|
insulin glargine (rDNA origin)
|
sanofi-aventis
|
Antidiabetic agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Livostin Eye Drops
|
levocabastine HCl
|
Novartis Pharmaceuticals
|
Histamine H1-antagonist
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Lyrica
|
pregabalin
|
Pfizer
|
Analgesic agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Nasacort AQ
|
triamcinolone acetonide
|
sanofi-aventis
|
Corticosteroid
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Prezista
|
darunavir ethanolate
|
Janssen-Ortho
|
Human immunodeficiency virus (HIV) protease inhibitor
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Tegretol
|
carbamazepine
|
Novartis Pharmaceuticals
|
Anticonvulsant - Antimanic - Symptomatic relief of trigeminal neuralgia
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/15/2010
|
|
Thelin
|
sitaxsentan sodium
|
Pfizer
|
Endothelin receptor antagonist
|
New safety information: in the contraindications and adverse reactions sections
|
08/15/2010
|
|
Tofranil
|
imipramine HCl
|
Novartis Pharmaceuticals
|
Antidepressant
|
New safety information: in the warnings and precautions section
|
08/15/2010
|
|
Voltaren Ophtha
|
diclofenac sodium
|
Novartis Pharmaceuticals
|
Analgesic - Anti-inflammatory
|
New safety information: in the adverse reactions section
|
08/15/2010
|
|
Zocor
|
simvastatin
|
Merck Frosst
|
Lipid metabolism regulator
|
New safety information: in the warnings and precautions section
|
08/15/2010
|
|
Zocor
|
simvastatin
|
Merck Frosst
|
Lipid metabolism regulator
|
New indication: use in pediatric patients 10-17 years old with heterozygous familial hypercholesterolemia
|
08/15/2010
|
|
Adacel
|
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
|
sanofi pasteur
|
Active immunizing agent
|
New safety information: in the adverse reactions section
|
08/01/2010
|
|
CO Atorvastatin
|
atorvastatin calcium
|
Cobalt
|
Lipid metabolism regulator
|
New product
|
08/01/2010
|
|
Cortifoam
|
hydrocortisone acetate
|
Paladin
|
Rectal anti-inflammatory corticosteroid foam
|
Reinstated product
|
08/01/2010
|
|
Desferal
|
deferoxamine mesylate
|
Novartis Pharmaceuticals
|
Iron and aluminum chelating agent
|
New safety information: in the adverse reactions section
|
08/01/2010
|
|
EMLA
|
lidocaine/prilocaine
|
AstraZeneca
|
Topical anesthetic for dermal analgesia
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/01/2010
|
|
Estalis
|
estradiol-17β/norethindrone acetate
|
Novartis Pharmaceuticals
|
Estrogen - Progestin
|
New safety information: in the adverse reactions section
|
08/01/2010
|
|
Finacea
|
azelaic acid
|
Bayer
|
Antirosacea agent
|
New molecular entity
|
08/01/2010
|
|
Ixiaro
|
inactivated japanese encephalitis virus (attenuated strain SA14-14-2 produced in vero cells)
|
Intercell AG
|
Active immunizing agent
|
New product
|
08/01/2010
|
|
Letrozole
|
letrozole
|
Cobalt
|
Antitumor agent - Inhibitor of estrogen biosynthesis - Nonsteroidal aromatase inhibitor
|
New product
|
08/01/2010
|
|
ratio-Ramipril
|
ramipril
|
ratiopharm
|
Angiotensin converting enzyme inhibitor
|
New dosage strength: 15 mg capsule
|
08/01/2010
|
|
Rituxan
|
rituximab
|
Roche
|
Antineoplastic
|
New safety information: in the contraindications and warnings and precautions sections
|
08/01/2010
|
|
Sandoz-Finasteride
|
finasteride
|
Sandoz
|
Type II 5 alpha-reductase inhibitor
|
New product
|
08/01/2010
|
|
Singulair
|
montelukast sodium
|
Merck Frosst
|
Leukotriene receptor antagonist
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
08/01/2010
|
|
Statex
|
morphine sulfate
|
Pharmascience
|
Opioid analgesic
|
Reinstated product
|
08/01/2010
|
|
Sutent
|
sunitinib malate
|
Pfizer
|
Anti-Tumour agent - Tyrosine kinase inhibitor
|
New safety information: in the adverse reactions section
|
08/01/2010
|
|
Triple Antibiotic Ointment
|
bacitracin zinc/gramicidin/polymyxin B sulfate
|
Taro
|
Antibiotic
|
New product
|
08/01/2010
|
|
Ultram
|
tramadol HCl
|
Janssen-Ortho
|
Opioid analgesic
|
New product
|
08/01/2010
|
|
Victoza
|
liraglutide
|
Novo Nordisk
|
Human glucagon like peptide-1 (GLP-1)
|
New molecular entity
|
08/01/2010
|
|
Adcirca
|
tadalafil
|
Lilly
|
cGMP-specific phosphodiesterase type 5 inhibitor
|
New product
|
07/15/2010
|
|
BioGaia Chewable Tablets
|
lactobacillus reuteri protectis
|
Ferring
|
Natural health product - Probiotic
|
New product
|
07/15/2010
|
|
BioGaia Drops
|
lactobacillus reuteri protectis
|
Ferring
|
Natural health product - Probiotic
|
New product
|
07/15/2010
|
|
B-natal Lozenge
|
pyridoxine HCl
|
Ferring
|
Natural health product
|
New product
|
07/15/2010
|
|
B-natal Therapop
|
vitamin B6
|
Ferring
|
Natural health product
|
New product
|
07/15/2010
|
|
Celebrex
|
celecoxib
|
Pfizer
|
Analgesic - Anti-inflammatory
|
New safety information: in the adverse reactions section
|
07/15/2010
|
|
Champix
|
varenicline tartrate
|
Pfizer
|
Smoking cessation aid
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/15/2010
|
|
Effient
|
prasugrel HCl
|
Lilly
|
Platelet aggregation inhibitor
|
New molecular entity
|
07/15/2010
|
|
Ezetrol
|
ezetimibe
|
Merck Frosst-Schering
|
Cholesterol absorption inhibitor
|
New safety information: in the adverse reactions section
|
07/15/2010
|
|
GlucaGen
|
glucagon
|
Novo Nordisk
|
Hyperglycemic agent
|
New product
|
07/15/2010
|
|
Januvia
|
sitagliptin phosphate
|
Merck Frosst
|
DPP-4 Inhibitor - Incretin enhancer - Oral antihyperglycemic agent
|
New indication: in combination with metformin and a sulfonylurea in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise, and dual therapy with these agents, do not provide adequate glycemic control
|
07/15/2010
|
|
Januvia
|
sitagliptin phosphate
|
Merck Frosst
|
DPP-4 Inhibitor - Incretin enhancer - Oral antihyperglycemic agent
|
New safety information: in the adverse reactions section
|
07/15/2010
|
|
Kytril
|
granisetron HCl
|
Roche
|
Antiemetic
|
New full monograph, previously availability only
|
07/15/2010
|
|
MacroBID
|
nitrofurantoin monohydrate/macrocrystals
|
Warner Chilcott
|
Urinary tract antibacterial
|
New full monograph, previously availability only
|
07/15/2010
|
|
Mezavant
|
5-ASA
|
Shire
|
Lower gastrointestinal anti-inflammatory
|
New safety information: in the adverse reactions section
|
07/15/2010
|
|
Naprosyn
|
naproxen
|
Roche
|
Nonsteroidal anti-inflammatory drug (NSAID)
|
New full monograph, previously availability only
|
07/15/2010
|
|
Pepcid Tablets
|
famotidine
|
Merck Frosst
|
Histamine H2-receptor antagonist
|
New safety information: in the adverse reactions section
|
07/15/2010
|
|
PMS-Letrozole
|
letrozole
|
Pharmascience
|
Antitumor agent - Inhibitor of estrogen biosynthesis - Nonsteroidal aromatase inhibitor
|
New product
|
07/15/2010
|
|
Polyderm
|
bacitracin zinc/polymyxin B sulfate
|
Taro
|
Antibiotic
|
New product
|
07/15/2010
|
|
Proleukin
|
aldesleukin
|
Novartis Pharmaceuticals
|
Biological response modifier
|
New safety information: in the adverse reactions section
|
07/15/2010
|
|
Rilutek
|
riluzole
|
sanofi-aventis
|
Antiglutamate
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/15/2010
|
|
Rythmol
|
propafenone HCl
|
Abbott
|
Antiarrhythmic
|
New full monograph, previously availability only
|
07/15/2010
|
|
TuZen
|
lactobacillus plantarum 299v
|
Ferring
|
Natural health product - Probiotic
|
New product
|
07/15/2010
|
|
Accutane Roche
|
isotretinoin
|
Roche
|
Nodular/inflammatory and conglobate acne therapy
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
Actemra
|
tocilizumab
|
Roche
|
Interleukin receptor inhibitor
|
New molecular entity
|
07/01/2010
|
|
Butrans
|
buprenorphine
|
Purdue Pharma
|
Opioid analgesic
|
New product: patch
|
07/01/2010
|
|
Cancidas
|
caspofungin acetate
|
Merck Frosst
|
Antifungal
|
New safety information: in the adverse reactions section
|
07/01/2010
|
|
Crestor
|
rosuvastatin calcium
|
AstraZeneca
|
Lipid metabolism regulator
|
New safety information: in the adverse reactions section
|
07/01/2010
|
|
Ebixa
|
memantine HCl
|
Lundbeck
|
N-methyl-D-aspartate (NMDA) receptor
|
New safety information: in the warnings and precautions section
|
07/01/2010
|
|
Erbitux
|
cetuximab
|
Bristol-Myers Squibb/ImClone LLC
|
Antineoplastic
|
New indication: for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma after failure of both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine, whose tumours have a wild-type (non-mutated) Kirsten rat sarcoma (KRAS) gene
|
07/01/2010
|
|
Erbitux
|
cetuximab
|
Bristol-Myers Squibb/ImClone LLC
|
Antineoplastic
|
New safety information: in the adverse reactions section
|
07/01/2010
|
|
Humira
|
adalimumab
|
Abbott
|
Biological response modifier
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
Invirase
|
saquinavir mesylate
|
Roche
|
Antiretroviral agent - HIV protease inhibitor
|
New safety information: in the contraindications, warnings and precautions, adverse reactions, and drug interactions sections
|
07/01/2010
|
|
Isentress
|
raltegravir potassium
|
Merck Frosst
|
Human immunodeficiency virus integrase strand transfer inhibitor
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
Kivexa
|
abacavir sulfate/lamivudine
|
GlaxoSmithKline - Shire
|
Antiretroviral agent
|
New safety information: in the warnings and precautions section
|
07/01/2010
|
|
Levaquin
|
levofloxacin
|
Janssen-Ortho
|
Antibacterial
|
New safety information: in the adverse reactions section
|
07/01/2010
|
|
Losec Capsules
|
omeprazole
|
AstraZeneca
|
H+, K+-ATPase Inhibitor
|
New safety information: in the drug interactions section
|
07/01/2010
|
|
Losec Tablets
|
omeprazole magnesium
|
AstraZeneca
|
H+, K+-ATPase Inhibitor
|
New safety information: in the drug interactions section
|
07/01/2010
|
|
Mirena
|
levonorgestrel
|
Bayer
|
Progestogen
|
New indication: treatment of idiopathic menorrhagia following appropriate diagnostic investigation in women accepting the contraceptive effect of Mirena
|
07/01/2010
|
|
Mirena
|
levonorgestrel
|
Bayer
|
Progestogen
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
Pegetron
|
peginterferon alfa-2b/ribavirin
|
Schering-Plough
|
Antiviral agent plus biological response modifier
|
New safety information: in the adverse reactions section
|
07/01/2010
|
|
Priorix-Tetra
|
measles, mumps, rubella and varicella vaccine, live, attenuated
|
GlaxoSmithKline
|
Active immunizing agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
Seroquel
|
quetiapine fumarate
|
AstraZeneca
|
Antipsychotic agent
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
07/01/2010
|
|
Seroquel XR
|
quetiapine fumarate
|
AstraZeneca
|
Psychotropic agent
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
07/01/2010
|
|
Sprycel
|
dasatinib
|
Bristol-Myers Squibb
|
Protein-tyrosine kinase inhibitor
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
Suprefact
|
buserelin acetate
|
sanofi-aventis
|
Luteinizing hormone-releasing hormone (LHRH) analog
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
Teva-Amlodipine
|
amlodipine besylate
|
Teva Canada
|
Antianginal - Antihypertensive
|
New product
|
07/01/2010
|
|
Teva-Atenolol
|
atenolol
|
Teva Canada
|
Beta-adrenergic receptor blocking agent
|
New product
|
07/01/2010
|
|
Teva-Citalopram
|
citalopram HBr
|
Teva Canada
|
Antidepressant
|
New product
|
07/01/2010
|
|
Teva-Enalapril
|
enalapril maleate
|
Teva Canada
|
Angiotensin converting enzyme inhibitor
|
New product
|
07/01/2010
|
|
Teva-Enalapril/HCTZ
|
enalapril/hydrochlorothiazide
|
Teva Canada
|
Angiotensin converting enzyme inhibitor - Diuretic
|
New product
|
07/01/2010
|
|
Teva-Ketotifen
|
ketotifen fumarate
|
Teva Canada
|
Antiallergic - Pediatric asthma prophylactic
|
New product
|
07/01/2010
|
|
Teva-Lansoprazole
|
lansoprazole
|
Teva Canada
|
H+, K+-ATPase inhibitor
|
New product
|
07/01/2010
|
|
Teva-Topiramate
|
topiramate
|
Teva Canada
|
Antiepileptic - Migraine prophylaxis
|
New Product
|
07/01/2010
|
|
Trizivir
|
abacavir sulfate/lamivudine/zidovudine
|
GlaxoSmithKline - Shire
|
Antiretroviral agent
|
New safety information: in the warnings and precautions section
|
07/01/2010
|
|
Videx EC
|
didanosine
|
Bristol-Myers Squibb
|
Antiretroviral agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
07/01/2010
|
|
HMG-CoA Reductase Inhibitors
|
atorvastatin calcium/fluvastatin sodium/lovastatin/pravastatin sodium/rosuvastatin calcium/simvastatin
|
CPhA Monograph
|
Lipid metabolism regulator - Statins
|
Completely updated monograph
|
06/15/2010
|
|
Afinitor
|
everolimus
|
Novartis Pharmaceuticals
|
Antineoplastic agent (mTOR kinase inhibitor)
|
New molecular entity
|
06/15/2010
|
|
Apo-Atorvastatin
|
atorvastatin calcium
|
Apotex
|
Lipid metabolism regulator
|
New product
|
06/15/2010
|
|
Azarga
|
brinzolamide/timolol maleate
|
Alcon
|
Elevated intraocular pressure therapy
|
New product
|
06/15/2010
|
|
Cholestyramine
|
cholestyramine resin
|
CPhA Monograph
|
Antidiarrheal - Antihypercholesterolemic - Bile acid sequestrant
|
Completely updated monograph
|
06/15/2010
|
|
CO Memantine
|
memantine HCl
|
Cobalt
|
N-methyl-D-aspartate (NMDA) receptor antagonist
|
New product
|
06/15/2010
|
|
Cosopt
|
dorzolamide HCl/timolol maleate
|
Merck Frosst
|
Elevated intraocular pressure therapy
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
06/15/2010
|
|
Florastor
|
Saccharomyces boulardii lyo
|
Medical Futures
|
Natural health product
|
New product
|
06/15/2010
|
|
Teva-Atorvastatin
|
atorvastatin calcium
|
Teva Canada
|
Lipid metabolism regulator
|
New product
|
06/15/2010
|
|
Nozinan
|
methotrimeprazine HCl
|
sanofi-aventis
|
Neuroleptic
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
06/15/2010
|
|
PMS-Atorvastatin
|
atorvastatin calcium
|
Pharmascience
|
Lipid metabolism regulator
|
New product
|
06/15/2010
|
|
Proferrin
|
heme iron polypeptide
|
Medical Futures
|
Natural health product
|
New product
|
06/15/2010
|
|
RAN-Atorvastatin
|
atorvastatin calcium
|
Ranbaxy
|
Lipid metabolism regulator
|
New product
|
06/15/2010
|
|
ratio-Atorvastatin
|
atorvastatin calcium
|
ratiopharm
|
Lipid metabolism regulator
|
New product
|
06/15/2010
|
|
Suprefact Depot
|
buserelin acetate
|
sanofi-aventis
|
Luteinizing hormone-releasing hormone (LHRH) analog
|
New safety information: in the adverse reactions section
|
06/15/2010
|
|
Topamax
|
topiramate
|
Janssen-Ortho
|
Antiepileptic - Migraine prophylaxis
|
New safety information: in the warnings and precautions section
|
06/15/2010
|
|
Androcur/Androcur Depot
|
cyproterone acetate
|
Bayer
|
Antiandrogen
|
New safety information: in the adverse reactions section
|
06/01/2010
|
|
AndroGel
|
testosterone
|
Solvay Pharma
|
Androgens
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
06/01/2010
|
|
CellCept
|
mycophenolate mofetil
|
Roche
|
Immunosuppressant
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
06/01/2010
|
|
COLD-FX
|
North American ginseng (Panax quinquefolius)
|
Afexa Life Sciences
|
Natural health product
|
New dosage strength: 300 mg capsule
|
06/01/2010
|
|
CO Olanzapine
|
olanzapine
|
Cobalt
|
Antipsychotic
|
New product
|
06/01/2010
|
|
CO Olanzapine ODT
|
olanzapine
|
Cobalt
|
Antipsychotic
|
New product
|
06/01/2010
|
|
Doribax
|
doripenem
|
Janssen-Ortho
|
Antibacterial
|
New safety information: in the adverse reactions section
|
06/01/2010
|
|
Enbrel
|
etanercept
|
Amgen
|
Biological response modifier
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
06/01/2010
|
|
Extavia
|
interferon beta-1b
|
Novartis Pharmaceuticals
|
Immunomodulator
|
New molecular entity
|
06/01/2010
|
|
Ilaris
|
canakinumab
|
Novartis Pharmaceuticals
|
Immunomodulatory Agent
|
New molecular entity
|
06/01/2010
|
|
Micatin
|
miconazole nitrate
|
WellSpring
|
Topical antifungal
|
Reinstated product
|
06/01/2010
|
|
Pegasys
|
peginterferon alfa-2a
|
Roche
|
Biological response modifier
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
06/01/2010
|
|
Pegasys RBV
|
peginterferon alfa-2a/ribavirin
|
Roche
|
Antiviral agent - Biological response modifier
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
06/01/2010
|
|
Rebif
|
interferon beta-1a
|
EMD Serono
|
Immunomodulator
|
New safety information: in the adverse reactions section
|
06/01/2010
|
|
Toloxin
|
digoxin
|
MM Therapeutics
|
Cardiotonic glycoside
|
New product
|
06/01/2010
|
|
Zometa Concentrate
|
zoledronic acid
|
Novartis Pharmaceuticals
|
Bone metabolism regulator
|
New safety information: in the adverse reactions section
|
06/01/2010
|
|
Apidra
|
insulin glulisine (recombinant DNA origin)
|
sanofi-aventis
|
Antidiabetic agent
|
New indication: extension of the indication to include pediatric population 6 years and older
|
05/15/2010
|
|
Apidra
|
insulin glulisine (recombinant DNA origin)
|
sanofi-aventis
|
Antidiabetic agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
05/15/2010
|
|
Apo-Granisetron
|
granisetron HCl
|
Apotex
|
5-HT3 receptor antagonist - Antiemetic
|
New product
|
05/15/2010
|
|
Avastin
|
bevacizumab
|
Roche
|
Antineoplastic
|
New indication: as a single agent, for the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy
|
05/15/2010
|
|
BeneFIX
|
coagulation factor IX (recombinant) (nonacog alfa)
|
Wyeth Canada
|
Antihemorrhagic blood boagulation factor IX
|
New safety information: in the adverse reactions section
|
05/15/2010
|
|
Crestor
|
rosuvastatin calcium
|
AstraZeneca
|
Lipid metabolism regulator
|
New indication: use in pediatric patients 10-17 years old with heterozygous familial hypercholesterolemia
|
05/15/2010
|
|
Cubicin
|
daptomycin
|
Sepracor
|
Antibacterial
|
New safety information: in the warnings and precautions section
|
05/15/2010
|
|
Emend IV
|
fosaprepitant
|
Merck Frosst
|
Neurokinin 1 (NK1) receptor antagonist
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
05/15/2010
|
|
Firmagon
|
degarelix acetate
|
Ferring
|
Gonadotropin-releasing hormone receptor antagonist
|
New molecular entity
|
05/15/2010
|
|
Lasix Special
|
furosemide
|
sanofi-aventis
|
Diuretic
|
New safety information: in the warnings and precautions and drug interactions sections
|
05/15/2010
|
|
Rasilez
|
aliskiren fumarate
|
Novartis Pharmaceuticals
|
Renin inhibitor
|
New safety information: in the drug interactions section
|
05/15/2010
|
|
Rasilez HCT
|
aliskiren fumarate/hydrochlorothiazide
|
Novartis Pharmaceuticals
|
Diuretic - Renin inhibitor
|
New Product
|
05/15/2010
|
|
Risperdal Consta
|
risperidone
|
Janssen-Ortho
|
Antipsychotic
|
New indication: bipolar disorder - as monotherapy maintenance treatment in patients with bipolar 1 disorder to delay occurrence of manic episodes
|
05/15/2010
|
|
Risperdal Consta
|
risperidone
|
Janssen-Ortho
|
Antipsychotic
|
New safety information: in the warnings and precautions section
|
05/15/2010
|
|
Sandoz-Letrozole
|
letrozole
|
Sandoz
|
Antitumor agent - Inhibitor of estrogen biosynthesis - Nonsteroidal aromatase inhibitor
|
New product issued under the NOC/C Policy
|
05/15/2010
|
|
Simponi
|
golimumab
|
Centocor
|
Tumour necrosis factor alpha (TNFα) inhibitor
|
New safety information: in the warnings and precautions and drug interactions sections
|
05/15/2010
|
|
Stalevo
|
carbidopa/entacapone/levodopa
|
Novartis Pharmaceuticals
|
Anti-parkinsonian dopaminergic agent
|
New dosage strengths: 75/18.75/200 mg and 125/31.25/200 mg tablets
|
05/15/2010
|
|
Xolair
|
omalizumab
|
Novartis Pharmaceuticals
|
IgE-neutralizing antibody (Anti-IgE)
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
05/15/2010
|
|
Yasmin
|
drospirenone/ethinyl estradiol
|
Bayer
|
Oral contraception
|
New safety information: in the adverse reactions section
|
05/15/2010
|
|
Zavesca
|
miglustat
|
Actelion
|
Glucosylceramide synthase inhibitor
|
New indication: to slow the progression of some of the neurological manifestations in patients with Niemann-Pick type C disease
|
05/15/2010
|
|
Zavesca
|
miglustat
|
Actelion
|
Glucosylceramide synthase inhibitor
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
05/15/2010
|
|
Vitamin K
|
phytonadione
|
CPhA monograph
|
Hypoprothrombinemia therapy
|
Completely updated monograph
|
05/01/2010
|
|
Cayston
|
aztreonam
|
Gilead Sciences
|
Antibiotic
|
New molecular entity
|
05/01/2010
|
|
Celsentri
|
maraviroc
|
Pfizer
|
CCR5 antagonist
|
New indication: use in treatment-naive patients infected with CCR5-tropic HIV-1
|
05/01/2010
|
|
Cervarix
|
recombinant human papillomavirus type 16 L1 protein /recombinant human papillomavirus type 18 L1 protein
|
GlaxoSmithKline
|
Active immunizing agent
|
New product
|
05/01/2010
|
|
Emend
|
aprepitant
|
Merck Frosst
|
Neurokinin 1 (NK1) receptor antagonist
|
New safety information: in the adverse reactions section
|
05/01/2010
|
|
Forteo
|
teriparatide (rDNA origin)
|
Lilly
|
Bone formation agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
05/01/2010
|
|
Heparin: Unfractionated
|
heparin sodium
|
CPhA monograph
|
Anticoagulant
|
Completely updated monograph
|
05/01/2010
|
|
Monovisc
|
sodium hyaluronate
|
Helix Biopharma
|
Synovial fluid replacement/replenishment
|
New product
|
05/01/2010
|
|
Prevnar 13
|
pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)
|
Wyeth Canada
|
Active immunizing agent
|
New product
|
05/01/2010
|
|
Prezista
|
darunavir ethanolate
|
Janssen-Ortho
|
Human immunodeficiency virus (HIV) protease inhibitor
|
New indication: extension of the indication to include pediatric population 6 years and older
|
05/01/2010
|
|
Prezista
|
darunavir ethanolate
|
Janssen-Ortho
|
Human immunodeficiency virus (HIV) protease inhibitor
|
New dosage strength: 75 mg tablets for the pediatric patient population
|
05/01/2010
|
|
Primovist
|
gadoxetate disodium
|
Bayer
|
Intravenous contrast enhancement agent for magnetic resonance imaging (MRI)
|
New product
|
05/01/2010
|
|
Recothrom
|
thrombin alfa (recombinant)
|
Bayer
|
Coagulation factor
|
New product
|
05/01/2010
|
|
Sustiva
|
efavirenz
|
Bristol-Myers Squibb
|
Antiretroviral agent
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
05/01/2010
|
|
Tysabri
|
natalizumab
|
Biogen Idec
|
Selective adhesion molecule inhibitor
|
New safety information: in the adverse reactions section
|
05/01/2010
|
|
Vaniqa
|
eflornithine HCl
|
Triton Pharma
|
Hair growth inhibitor
|
Reinstated product
|
05/01/2010
|
|
Vfend
|
voriconazole
|
Pfizer
|
Antifungal
|
New safety information: in the drug interactions section
|
05/01/2010
|
|
Vibramycin
|
doxycycline hyclate
|
Pfizer
|
Antibiotic
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
05/01/2010
|
|
Vyvanse
|
lisdexamfetamine dimesylate
|
Shire
|
Central nervous system stimulant for attention deficit hyperactivity disorder
|
New dosage strengths: 20 mg, 40 mg, and 60 mg tablets
|
05/01/2010
|
|
Xyrem
|
sodium oxybate
|
Valeant
|
CNS depressant
|
New safety information: in the adverse reactions section
|
05/01/2010
|
|
Apo-Sibutramine
|
sibutramine HCl monohydrate
|
Apotex
|
Anorexiant -Antiobesity agent
|
New product
|
04/15/2010
|
|
Arthrotec
|
diclofenac sodium/misoprostol
|
Pfizer
|
Mucosal protective agent - NSAID
|
New safety information: in the drug interactions and adverse reactions sections
|
04/15/2010
|
|
Crestor
|
rosuvastatin calcium
|
AstraZeneca
|
Lipid metabolism regulator
|
New indication: To reduce the risk of non-fatal myocardial infarction or stroke, or coronary revascularization in patients without documented cardiovascular events but with at least two risk factors for cardiovascular disease
|
04/15/2010
|
|
Crestor
|
rosuvastatin calcium
|
AstraZeneca
|
Lipid metabolism regulator
|
New safety information: in the adverse reactions section
|
04/15/2010
|
|
Emend
|
aprepitant
|
Merck Frosst
|
Neurokinin 1 (NK1) receptor antagonist
|
Revised indication: prevention of nausea and vomiting in women due to treatment with moderately emetogenic cancer chemotherapy
|
04/15/2010
|
|
Emend IV
|
fosaprepitant
|
Merck Frosst
|
Neurokinin 1 (NK1) receptor antagonist
|
Revised indication: prevention of nausea and vomiting in women due to treatment with moderately emetogenic cancer chemotherapy
|
04/15/2010
|
|
Mirena
|
levonorgestrel
|
Bayer
|
Progestogen
|
New safety information: in the warnings and precautions and adverse reactions sections
|
04/15/2010
|
|
PMS-Finasteride
|
finasteride
|
Pharmascience
|
Type II 5 alpha-reductase inhibitor
|
New product
|
04/15/2010
|
|
Prinzide
|
hydrochlorothiazide/lisinopril
|
Merck Frosst
|
Angiotensin converting enzyme inhibitor - Diuretic
|
New safety information: in the drug interactions section
|
04/15/2010
|
|
ratio-Finasteride
|
finasteride
|
ratiopharm
|
Type II 5 alpha-reductase inhibitor
|
New product
|
04/15/2010
|
|
Travatan
|
travoprost
|
Alcon
|
Elevated intraocular pressure therapy - Prostaglandin F2α analogue
|
New safety information: in the adverse reactions section
|
04/15/2010
|
|
Vasotec
|
enalapril
|
Merck Frosst
|
Angiotensin converting enzyme inhibitor
|
New safety information: in the drug interactions section
|
04/15/2010
|
|
Endometrin
|
progesterone
|
Ferring
|
Progestin
|
New product: vaginal effervescent tablets
|
04/01/2010
|
|
Jurnista
|
hydromorphone HCl
|
Janssen-Ortho
|
Opioid analgesic
|
New product
|
04/01/2010
|
|
Allegra-D
|
fexofenadine HCl/pseudoephedrine HCl
|
sanofi-aventis
|
Histamine H1-receptor antagonist - Sympathomimetic amine
|
New safety information: in the adverse reactions section
|
04/01/2010
|
|
Alvesco
|
ciclesonide
|
Altana
|
Corticosteroid for oral inhalation
|
New safety information: in the adverse reactions section
|
04/01/2010
|
|
Ansaid
|
flurbiprofen
|
Pfizer
|
Nonsteroidal anti-inflammatory drug (NSAID)
|
New safety information: in the drug interactions section
|
04/01/2010
|
|
Apo-Tramadol/Acet
|
acetaminophen/tramadol HCl
|
Apotex
|
Centrally acting analgesic
|
New product
|
04/01/2010
|
|
Children's Motrin Cold
|
ibuprofen/pseudoephedrine HCl
|
McNeil Consumer Healthcare
|
Analgesic - Antipyretic - Decongestant
|
New product
|
04/01/2010
|
|
Cyclen
|
ethinyl estradiol/norgestimate
|
Janssen-Ortho
|
Oral contraceptive
|
New safety information: in the contraindications, drug interactions, and adverse reactions sections
|
04/01/2010
|
|
Duragesic Mat
|
fentanyl
|
Janssen-Ortho
|
Opioid analgesic
|
New safety information: in the drug interactions section
|
04/01/2010
|
|
Nitrates
|
isosorbide dinitrate/isosorbide-5-mononitrate/nitroglycerin
|
CPhA Monograph
|
Antianginal - Antihypertensive
|
Completely updated monograph
|
04/01/2010
|
|
Pegetron
|
peginterferon alfa-2b/ribavirin
|
Schering-Plough
|
Antiviral agent plus biological response modifier
|
New dosing and extension of indication: treatment of adult patients (18 years of age and older) with chronic hepatitis C who have compensated liver disease and are positive for HCV-RNA, including patients who have not received previous treatment or who failed prior treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy
|
04/01/2010
|
|
Premarin Vaginal Cream
|
conjugated estrogens
|
Wyeth Canada
|
Estrogenic hormones
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
04/01/2010
|
|
Provera
|
medroxyprogesterone acetate
|
Pfizer
|
Progestin
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
04/01/2010
|
|
Rasilez
|
aliskiren fumarate
|
Novartis Pharmaceuticals
|
Renin inhibitor
|
New indication: concomitant use with angiotensin II ATI receptor blockers
|
04/01/2010
|
|
ratio-Rivastigmine
|
rivastigmine hydrogen tartrate
|
ratiopharm
|
Cholinesterase inhibitor
|
New product
|
04/01/2010
|
|
Taxol
|
paclitaxel
|
Bristol-Myers Squibb
|
Antineoplastic
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
04/01/2010
|
|
Tri-Cyclen
|
ethinyl estradiol/norgestimate
|
Janssen-Ortho
|
Oral contraceptive
|
New safety information: in the contraindications, drug interactions, and adverse reactions sections
|
04/01/2010
|
|
Trileptal
|
oxcarbazepine
|
Novartis Pharmaceuticals
|
Antiepileptic
|
New safety information: in the warnings and precautions section
|
04/01/2010
|
|
Vectibix
|
panitumumab
|
Amgen
|
Antineoplastic
|
New safety information: in the adverse reactions section
|
04/01/2010
|
|
Zeftera
|
ceftobiprole medocaril
|
Janssen-Ortho
|
Antibacterial agent
|
New safety information: in the adverse reactions section
|
04/01/2010
|
|
Zestoretic
|
hydrochlorothiazide/lisinopril
|
AstraZeneca
|
Angiotensin converting enzyme inhibitor - Diuretic
|
New safety information: in the drug interactions and adverse reactions sections
|
04/01/2010
|
|
Zevalin
|
ibritumomab tiuxetan
|
Bayer
|
Therapeutic radiopharmaceutical
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
04/01/2010
|
|
Adriamycin PFS
|
doxorubicin HCl
|
Pfizer
|
Antineoplastic
|
New safety information: in the drug interactions section
|
03/15/2010
|
|
Altace
|
ramipril
|
sanofi-aventis
|
Angiotensin converting enzyme inhibitor
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
03/15/2010
|
|
Arimidex
|
anastrozole
|
AstraZeneca
|
Nonsteroidal aromatase inhibitor
|
New safety information: in the adverse reactions section
|
03/15/2010
|
|
Cyclomen
|
danazol
|
sanofi-aventis
|
Pituitary gonadotropin inhibitor
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
03/15/2010
|
|
Fosrenol
|
lanthanum carbonate hydrate
|
Shire
|
Phosphate binder
|
New safety information: in the drug interactions section
|
03/15/2010
|
|
Lasix
|
furosemide
|
sanofi-aventis
|
Diuretic
|
New safety information: in the warnings and precautions and drug interactions sections
|
03/15/2010
|
|
Magnevist
|
gadopentetate dimeglumine
|
Bayer
|
Contrast enhancement agent for magnetic resonance imaging (MRI)
|
New safety information: in the adverse reactions section
|
03/15/2010
|
|
Maxalt
|
rizatriptan benzoate
|
Merck Frosst
|
Migraine therapy
|
New safety information: in the adverse reactions section
|
03/15/2010
|
|
Neurontin
|
gabapentin
|
Pfizer
|
Antiepileptic
|
New safety information: in the adverse reactions section
|
03/15/2010
|
|
Nexavar
|
sorafenib
|
Bayer
|
Antineoplastic - Multikinase inhibitor
|
New safety information: in the adverse reactions section
|
03/15/2010
|
|
Nitoman
|
tetrabenazine
|
Biovail Pharmaceuticals
|
Monoamine depleting agent
|
New safety information: in the drug interactions section
|
03/15/2010
|
|
Orencia
|
abatacept
|
Bristol-Myers Squibb
|
Selective co-stimulation modulator
|
New indication: when used as first-line treatment in recently diagnosed patients who have not been previously treated with Methotrexate (MTX), Orencia should be given in combination with MTX
|
03/15/2010
|
|
Orencia
|
abatacept
|
Bristol-Myers Squibb
|
Selective co-stimulation modulator
|
New safety information: in the adverse reactions section
|
03/15/2010
|
|
Ortho-Cept
|
desogestrel/ethinyl estradiol
|
Janssen-Ortho
|
Oral contraceptive
|
New safety information: in the drug interactions and adverse reactions sections
|
03/15/2010
|
|
Premarin Tablets
|
conjugated estrogens
|
Wyeth Canada
|
Estrogenic hormones
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
03/15/2010
|
|
RotaTeq
|
rotavirus vaccine, live, oral, pentavalent
|
Merck Frosst
|
Live, oral pentavalent vaccine against rotavirus gastroenteritis
|
New safety information: in the warnings and precautions section
|
03/15/2010
|
|
Taxotere
|
docetaxel
|
sanofi-aventis
|
Antineoplastic
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
03/15/2010
|
|
Tracleer
|
bosentan
|
Actelion
|
Endothelin receptor antagonist
|
New safety information: in the drug interactions section
|
03/15/2010
|
|
Zestril
|
lisinopril
|
AstraZeneca
|
Angiotensin converting enzyme inhibitor
|
New safety information: in the drug interactions and adverse reactions sections
|
03/15/2010
|
|
Zyclara
|
imiquimod
|
Graceway
|
Immune response modifier
|
New product
|
03/15/2010
|
|
Avelox, Avelox IV
|
moxifloxacin HCl
|
Bayer
|
Antibacterial agent
|
New safety information: in the warnings and precautions section
|
03/01/2010
|
|
Intelence
|
etravirine
|
Janssen-Ortho
|
Human immunodeficiency virus (HIV) non-nucleoside reverse transcriptase inhibitor
|
New safety information: in the adverse reactions section
|
03/01/2010
|
|
Micardis
|
telmisartan
|
Boehringer Ingelheim
|
Angiotensin II AT1 receptor blocker
|
New indication: risk reduction of cardiovascular morbidity in patients intolerant to angiotensin converting enzyme inhibitors
|
03/01/2010
|
|
Micardis
|
telmisartan
|
Boehringer Ingelheim
|
Angiotensin II AT1 receptor blocker
|
New safety information: in the drug interactions and adverse reactions sections
|
03/01/2010
|
|
Odan K-20
|
potassium chloride
|
Odan
|
Potassium supplement
|
New product
|
03/01/2010
|
|
PMS-Testosterone
|
testosterone undecanoate
|
Pharmascience
|
Androgen
|
New product
|
03/01/2010
|
|
Prograf
|
tacrolimus
|
Astellas
|
Immunosuppressant
|
New safety information: in the adverse reactions section
|
03/01/2010
|
|
Sandostatin/Sandostatin LAR
|
octreotide acetate
|
Novartis Pharmaceuticals
|
Synthetic octapeptide analogue of somatostatin
|
New safety information: in the adverse reactions section
|
03/01/2010
|
|
Sensipar
|
cinacalcet HCl
|
Amgen
|
Calcimimetic agent
|
New safety information: in the adverse reactions section
|
03/01/2010
|
|
Tarceva
|
erlotinib HCl
|
Roche
|
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
|
New safety information: in the warnings and precautions and adverse reactions sections
|
03/01/2010
|
|
Velcade
|
bortezomib mannitol boronic ester
|
Janssen-Ortho
|
Antineoplastic agent
|
New safety information: in the adverse reactions section
|
03/01/2010
|
|
Xeloda
|
capecitabine
|
Roche
|
Antineoplastic
|
New safety information: in the drug interactions and adverse reactions sections
|
03/01/2010
|
|
Xeloda
|
capecitabine
|
Roche
|
Antineoplastic
|
New indication: in combination with oxaliplatin for the treatment of metastatic colorectal cancer following failure of irinotecan-containing combination chemotherapy
|
03/01/2010
|
|
Xenical
|
orlistat
|
Roche
|
Antiobesity - Gastrointestinal lipase inhibitor
|
New safety information: in the warnings and precautions and drug interactions sections
|
03/01/2010
|
|
Vyvanse
|
lisdexamfetamine dimesylate
|
Shire
|
Central nervous system stimulant for attention deficit hyperactivity disorder
|
New molecular entity
|
02/15/2010
|
|
Aclasta
|
zoledronic acid
|
Novartis Pharmaceuticals
|
Bone metabolism regulator
|
New indication: the prevention of postmenopausal osteoporosis in women with osteopenia as a single intravenous infusion
|
02/15/2010
|
|
Aclasta
|
zoledronic acid
|
Novartis Pharmaceuticals
|
Bone metabolism regulator
|
New safety information: in the adverse reactions section
|
02/15/2010
|
|
Adderall XR
|
mixed salts amphetamine
|
Shire
|
CNS stimulant
|
New safety information: in the drug interactions section
|
02/15/2010
|
|
Avodart
|
dutasteride
|
GlaxoSmithKline
|
Type I and II 5 alpha-reductase inhibitor
|
New indication: use in combination with tamsulosin for the treatment of moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH) in men with enlarged prostates
|
02/15/2010
|
|
Besivance
|
besifloxacin
|
Bausch & Lomb
|
Antibacterial (ophthalmic)
|
New molecular entity
|
02/15/2010
|
|
Flagyl
|
metronidazole
|
sanofi-aventis
|
Antibacterial - Antiprotozoal
|
New safety information: in the adverse reactions section
|
02/15/2010
|
|
GD-amlodipine
|
amlodipine besylate
|
GenMed
|
Antianginal - Antihypertensive
|
New product
|
02/15/2010
|
|
Gleevec
|
imatinib mesylate
|
Novartis Pharmaceuticals
|
Protein kinase inhibitor
|
New indication: for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST
|
02/15/2010
|
|
Hepsera
|
adefovir dipivoxil
|
Gilead Sciences
|
Antiviral agent
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
02/15/2010
|
|
Januvia
|
sitagliptin phosphate
|
Merck Frosst
|
DPP-4 Inhibitor - Incretin enhancer - Oral antihyperglycemic agent
|
New indication: monotherapy - as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus and for whom metformin is inappropriate due to contraindications or intolerance
|
02/15/2010
|
|
Teva-Methylphenidate ER-C
|
methylphenidate HCl
|
Teva Canada
|
CNS Stimulant
|
New product
|
02/15/2010
|
|
Teva-Risedronate
|
risedronate sodium monohydrate
|
Teva Canada
|
Bone metabolism regulator
|
New product
|
02/15/2010
|
|
Teva-Salbutamol HFA
|
salbutamol sulphate
|
Teva Canada
|
Bronchodilator
|
New product
|
02/15/2010
|
|
Onglyza
|
saxagliptin HCl
|
Bristol-Myers Squibb
|
DPP-4 inhibitor - Incretin enhancer - Oral antihyperglycemic agent
|
New molecular entity
|
02/15/2010
|
|
RAN-Amlodipine
|
amlodipine besylate
|
Ranbaxy
|
Antianginal - Antihypertensive
|
New product
|
02/15/2010
|
|
RAN-Ramipril
|
ramipril
|
Ranbaxy
|
Angiotensin converting enzyme inhibitor
|
New product
|
02/15/2010
|
|
RAN-Ropinirole
|
ropinirole HCl
|
Ranbaxy
|
Antiparkinsonian agent - Dopamine agonist
|
New product
|
02/15/2010
|
|
RAN-Simvastatin
|
simvastatin
|
Ranbaxy
|
Lipid metabolism regulator
|
New product
|
02/15/2010
|
|
Topotecan for Injection
|
topotecan HCl
|
Sandoz
|
Antineoplastic
|
New product
|
02/15/2010
|
|
Atripla
|
efavirenz/emtricitabine/tenofovir disoproxil fumarate
|
Gilead Sciences
|
Antiretroviral agent
|
New safety information: in the warnings and precautions, adverse reactions, and drug interactions sections
|
02/01/2010
|
|
Camptosar
|
irinotecan HCl trihydrate
|
Pfizer
|
Antineoplastic
|
New safety information: in the warnings and precautions, adverse reactions sections
|
02/01/2010
|
|
Plavix
|
clopidogrel bisulfate
|
sanofi-aventis
|
Platelet aggregation inhibitor
|
New safety information: in the warnings and precautions and drug interactions sections
|
02/01/2010
|
|
Iressa
|
gefitinib
|
AstraZeneca
|
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
|
New indication: for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK
|
02/01/2010
|
|
Acetylcysteine Injection
|
acetylcysteine
|
Alveda
|
Antidote for acetaminophen poisoning - Mucolytic
|
New product
|
01/15/2010
|
|
Enbrel
|
etanercept
|
Amgen
|
Biological response modifier
|
New safety information: in the drug interactions and adverse reactions sections
|
01/15/2010
|
|
Hydralazine
|
hydralazine
|
CPhA monograph
|
Antihypertensive - Vasodilator
|
Completely updated monograph
|
01/15/2010
|
|
Propranolol
|
propranolol HCl
|
CPhA monograph
|
Beta-adrenergic receptor blocking agent, nonselective
|
Completely updated monograph
|
01/15/2010
|
|
Salazopyrin/Salazopyrin EN-tabs
|
sulfasalazine
|
Pfizer
|
Anti-inflammatory
|
New safety information: in the adverse reactions section
|
01/15/2010
|
|
Avamys
|
fluticasone furoate
|
GlaxoSmithKline
|
Corticosteroid for nasal use
|
New indication: treatment of perennial allergic rhinitis in pediatrics (2 years to < 12 years of age)
|
12/15/2009
|
|
Lamictal
|
lamotrigine
|
GlaxoSmithKline
|
Antiepileptic
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
12/15/2009
|
|
Methylene Blue Injection
|
methylene blue
|
Alveda
|
Antidote
|
New product
|
12/15/2009
|
|
Teva-Naratriptan
|
naratriptan HCl
|
Teva Canada
|
5-HT1 receptor agonist - Migraine therapy
|
New product
|
12/15/2009
|
|
Priorix-Tetra
|
measles, mumps, rubella and varicella vaccine, live, attenuated
|
GlaxoSmithKline
|
Active immunizing agent
|
New indication: active immunization against measles, mumps, rubella and varicella in individuals from 9 to 24 months of age.
|
12/15/2009
|
|
Relenza
|
zanamivir
|
GlaxoSmithKline
|
Antiviral agent
|
New safety information: in the adverse reactions, and warnings and precautions sections
|
12/15/2009
|
|
Sodium Chloride Injection
|
sodium chloride
|
Alveda
|
Diluent
|
New product
|
12/15/2009
|
|
Sterile Water for Injection
|
water
|
Alveda
|
Diluent
|
New product
|
12/15/2009
|
|
Tamiflu
|
oseltamivir phosphate
|
Roche
|
Antiviral agent
|
New product information: updated directions for emergency compounding
|
12/15/2009
|
|
Taro-Mometasone Lotion
|
mometasone furoate
|
Taro
|
Corticosteroid
|
New product
|
12/15/2009
|
© Canadian Pharmacists Association, 2010. All rights reserved.